Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, Hellerup, Denmark.
Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen.
Acta Derm Venereol. 2023 Nov 21;103:adv12616. doi: 10.2340/actadv.v103.12616.
Whether response to an interleukin (IL-17) inhibitor is different in patients with previous exposure to an IL-17 inhibitor compared with patients with exposure to biologics with other cytokine targets remains to be elucidated. Therefore, the aim of this study was to assess whether previous exposure to an IL-17A inhibitor was associated with worse response than exposure to (an)other biologic(s). All patients in the DERMBIO register treated with an IL-17A inhibitor (secukinumab or ixekizumab) were included. With an absolute Psoriasis Area and Severity Index (PASI) ≤ 2 as response, the proportion of responders treated with IL-17A inhibitors was assessed in patients previously treated with another IL-17A inhibitor and compared with patients with previous exposure to (an)other biologic(s), using a χ2 test. In total, 100, 93 and 83 patients with previous exposure to an IL-17A inhibitor and 414, 372 and 314 patients with previous exposure to (an) other biologic(s) were assessed after 3, 6 and 12 months, respectively. No differences in the proportion of patients achieving PASI ≤ 2 were observed between the 2 groups after 3 months (54% vs 57%, p = 0.59), 6months (70% vs 66%, p = 0.42) and 12 months (69% vs 60%, p = 0.14). In conclusion, when treating patients with IL-17A inhibitors the cytokine target of the previous biologic does not appear to affect the response.
是否在先前接触过白细胞介素（IL-17）抑制剂的患者与接触过其他细胞因子靶点生物制剂的患者中，对白细胞介素（IL-17）抑制剂的反应不同仍有待阐明。因此，本研究旨在评估先前接触白细胞介素（IL-17A）抑制剂是否与对（an）其他生物制剂的暴露相比，反应更差。DERMBIO 登记处接受白细胞介素（IL-17A）抑制剂（司库奇尤单抗或依奇珠单抗）治疗的所有患者均被纳入研究。以绝对银屑病面积和严重程度指数（PASI）≤2作为反应，采用卡方检验评估先前接受过其他白细胞介素（IL-17A）抑制剂治疗的患者中，接受白细胞介素（IL-17A）抑制剂治疗的患者中反应者的比例，并与先前接受过（an）其他生物制剂治疗的患者进行比较。分别在 3、6 和 12 个月时，评估了 100、93 和 83 例先前接受过白细胞介素（IL-17A）抑制剂治疗的患者和 414、372 和 314 例先前接受过（an）其他生物制剂治疗的患者。在 3 个月（54%比 57%，p=0.59）、6 个月（70%比 66%，p=0.42）和 12 个月（69%比 60%，p=0.14）时，两组患者达到 PASI≤2 的比例均无差异。当使用白细胞介素（IL-17A）抑制剂治疗患者时，先前生物制剂的细胞因子靶点似乎不会影响反应。
Acta Derm Venereol. 2023-11-21
J Dermatolog Treat. 2019-5
Acta Derm Venereol. 2021-10-26
Acta Derm Venereol. 2019-7-1
Am J Clin Dermatol. 2025-5
Am J Clin Dermatol. 2025-1
J Eur Acad Dermatol Venereol. 2022-8
Acta Derm Venereol. 2021-10-26
Acta Derm Venereol. 2020-12-14
Dermatol Online J. 2020-1-15
Zotero 插件